Egham, UK – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd. Renaissance, a clinical...
Latest News
EMERYVILLE, Calif. — Estrella Immunopharma, Inc. (NASDAQ: ESLA), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been dosed in the second cohort of its dose escalation study of Phase I/II STARLIGHT-1 trial for EB103,...
CHICAGO – Esya Labs, which is developing several ground-breaking novel research assays, today has announced that Novartis is among the first companies to use its technology. Novartis, a global healthcare company, has used a patented assay developed by Esya Labs to accelerate drug discovery efforts for Mucolipidosis Type IV, a rare inherited metabolic...
BRIGHTON, UK – ETD001, an investigational inhaled therapy for cystic fibrosis (CF), has demonstrated encouraging results in a small clinical trial, improving lung function more effectively than a placebo in patients who were not taking CFTR modulators. The findings were announced by Enterprise Therapeutics, the company developing the treatment. The...
Zurich, Switzerland – Glioblastoma is a particularly aggressive brain tumour that at present is incurable. Cancer doctors can extend patients’ life expectancy through operations, radiation, chemotherapy or surgical interventions. Nevertheless, half of patients die within twelve months of diagnosis. Drugs that are effective against brain tumours are difficult to find,...
DEER PARK, Ill. — Eton Pharmaceuticals (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary...
Cambridge, UK – AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the 1st-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval by the European Commission follows the positive opinion of...
PARIS, FRANCE, 22 April 2026 — Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has granted conditional marketing authorization for Ojemda® (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with pediatric low-grade-glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation,...
Brussels, Belgium – Multiple sclerosis (MS), an inflammatory disease of the central nervous system, affects more than 1 million people in Europe and an estimated 2.8 million worldwide. MS is characterized by an inflammation-related loss and damage of the myelin layer in the brain and spinal cord, which insulates the...
A group of more than 40 EU lawmakers backed the idea of an EU action plan for rare diseases, in a letter addressed to European Commission President Ursula von der Leyen.